4ORelationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial. (13th May 2019) - Loi, S; Schmid, P; Aktan, G; Karantza, V; Salgado, R